In September, more than 750 cancer patients, survivors and their loved ones from all 50 states, Washington, D.C., Puerto Rico and Guam, traveled to Washington, D.C., as part of the American Cancer Society Action Network’s annual Leadership Summit and Lobby Day.
Brittanny Groover, a cancer survivor from Dilliner, met with members of Pennsylvania’s congressional delegation to urge them to support policies that increase funding for cancer research and prevention programs and urge lawmakers to pass the Clinical Trial Modernization Act.
In the last 30 years, substantial and steady increases in federal cancer research funding have fueled discovery and innovation that has led to a 34% decline in cancer mortality rates. Advocates reminded lawmakers that this incredible momentum in the fight against cancer is fueled by sufficient funding at key agencies, including the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Centers for Disease Control and Prevention (CDC).
Groover also called on Pennsylvania lawmakers to support the bipartisan Clinical Trial Modernization Act, or CTMA. This legislation would make it easier for all people with cancer to participate in clinical trials, including those in underrepresented populations, like rural residents, older adults, certain racial and ethnic groups, and those with limited incomes.
The passage of CTMA is crucial to ensure more patients—regardless of their economic means or their geographic location—have a chance to enroll in clinical trials, ultimately giving more people a better chance in the face of a cancer diagnosis.
Dilliner’s Brittany Groover and other cancer survivors in Washington, DC lobbying Congress to pass funding for cancer research and prevention programs.
